Publications – Gercor

Liste des publications de l’année2024

Néant

Liste des publications de l’année2023

Néant

Liste des publications de l’année2022

Néant

Liste des publications de l’année2021

Néant

Liste des publications de l’année2020

Articles

Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group.
André T, Vernerey D, Im SA, et al. Bevacizumab as adjuvant treatment of colon cancer
Ann Oncol. 2020;31(2):246-256. doi:10.1016/j.annonc.2019.12.006
Small bowel adenocarcinoma: Results from a nationwide prospective ARCAD-NADEGE cohort study of 347 patients_
Aparicio T, Henriques J, Manfredi S
Int J Cancer. 2020;147(4):967-977. doi:10.1002/ijc.32860
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
Boilève A, Hilmi M, Gougis P, Cohen R, Rousseau B, Blanc JF, Ben Abdelghani M, Castanié H, Dahan L, Tougeron D, Metges JP, Tournigand C, Garcia-Larnicol ML, Vernerey D, Turpin A, Neuzillet C.
Eur J Cancer. 2020 Dec 3;143:55-63. doi: 10.1016/j.ejca.2020.10.027. Epub ahead of print. PMID: 33279854
Understanding the Prognostic Value of Primary Tumor Location and KRAS in Metastatic Colorectal Cancer: A Post Hoc Analysis of the OPTIMOX3 DREAM Phase III Stud
Chibaudel B, André T, Tournigand C,
Clin Colorectal Cancer. 2020;S1533-0028(20)30035-9. doi:10.1016/j.clcc.2020.02.012
Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer
Chibaudel B, Henriques J, Rakez M, Brenner B, Kim TW, Martinez-Villacampa M, Gallego-Plazas J, Cervantes A, Shim K, Jonker D, Guerin-Meyer V, Mineur L, Banzi C, Dewdney A, Dejthevaporn T, Bloemendal HJ, Roth A, Moehler M, Aranda E, Van Cutsem E, Tabernero J, Schmoll HJ, Hoff PM, André T, de Gramont A.
JAMA Netw Open. 2020 Oct 1;3(10):e2020425. doi: 10.1001/jamanetworkopen.2020.20425. PMID: 33074326; PMCID: PMC7573695
Patients atteints d’un cancer gastrique localisé MSI/dMMR, pas de chimiothérapie mais une immunothérapie périopératoire : l’essai de phase II GERCOR NEONIPIGA vient d’être ouvert au recrutement [Localized MSI/dMMR gastric cancer patients, perioperative im
Cohen R, Pudlarz T, Garcia-Larnicol ML
Bull Cancer. 2020;107(4):438-446. doi:10.1016/j.bulcan.2019.11.016
RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study.
Cohen R, Bennouna J, Meurisse A, Tournigand C, De La Fouchardière C, Tougeron D, Borg C, Mazard T, Chibaudel B, Garcia-Larnicol ML, Svrcek M, Vernerey D, Menu Y, André T
J Immunother Cancer. 2020 Nov;8(2):e001499. doi: 10.1136/jitc-2020-001499. PMID: 33148693.
Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).
de Mestier L, Lepage C, Baudin E
Dig Liver Dis. 2020;52(5):473-492. doi:10.1016/j.dld.2020.02.011
Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). J Clin Oncol
Delattre JF, Cohen R, Henriques J
J Clin Oncol. 2020;38(15):1702-1710. doi:10.1200/JCO.19.01960
COVID-19 epidemic: Proposed alternatives in the management of digestive cancers: A French intergroup clinical point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR).
Di Fiore F, Bouché O, Lepage C
Dig Liver Dis. 2020;52(6):597-603. doi:10.1016/j.dld.2020.03.031
Nutrition and physical activity professional education in gastrointestinal oncology: a national multidisciplinary survey
Hilmi M, Pellat A, Benoit O
BMJ Support Palliat Care. 2020;10(3):324-330. doi:10.1136/bmjspcare-2020-002342
Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
Kim S, Buecher B, André T
BMC Cancer. 2020;20(1):352. Published 2020 Apr 25. doi:10.1186/s12885-020-06841-1
Nutrition and physical activity professional education in gastrointestinal oncology: a national multidisciplinary survey
Hilmi M, Pellat A, Benoit O
BMJ Support Palliat Care. 2020;10(3):324-330. doi:10.1136/bmjspcare-2020-002342
Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR – PRODIGE Survey. Clin Colorectal Cancer
Ouali K, Turpin A, Neuzillet C, Rousseau B, Garcia-Larnicol ML, Tournigand C, Samalin E, Taieb J, André T, Cohen R
Clin Colorectal Cancer. 2020 Nov 14:S1533-0028(20)30158-4. doi: 10.1016/j.clcc.2020.11.004. Epub ahead of print. PMID: 33281064.
Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study
Pagès F, André T, Taieb J
Ann Oncol. 2020;31(7):921-929. doi:10.1016/j.annonc.2020.03.310
The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions
Pagès F, Taieb J, Laurent-Puig P, Galon J
Oncoimmunology. 2020 Aug 28;9(1):1812221
A comprehensive overview of promising biomarkers in stage II colorectal cancer
Parent P, Cohen R, Rassy E
Cancer Treat Rev. 2020;88:102059. doi:10.1016/j.ctrv.2020.102059
Fong’s Score in the Era of Modern Perioperative Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial
Makhloufi S, Turpin A, El Amrani M
Chemotherapy for Metastatic Colorectal Cancer: A Post Hoc Analysis of the GERCOR-MIROX Phase III Trial. Ann Surg Oncol. 2020;27(3):877-885. doi:10.1245/s10434-019-07976-7
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database
Salem ME, Yin J, Goldberg RM
Ann Oncol. 2020;31(4):480-486. doi:10.1016/j.annonc.2019.12.007
A new prognostic and predictive tool for shared decision making in stage III colon cancer
Sobrero AF, Puccini A, Shi Q
Eur J Cancer. 2020;138:182-188. doi:10.1016/j.ejca.2020.07.031
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)
Lièvre A, Turpin A, Ray-Coquard I, Le Malicot K, Thariat J, Ahle G, Neuzillet C, Paoletti X, Bouché O, Aldabbagh K, Michel P, Debieuvre D, Canellas A, Wislez M, Laurent L, Mabro M, Colle R, Hardy-Bessard AC, Mansi L, Colomba E, Bourhis J, Gorphe P, Pointreau Y, Idbaih A, Ursu R, Di Stefano AL, Zalcman G, Aparicio T
Management of digestive cancers during the COVID-19 second wave: A French intergroup point of view (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR).
Tougeron D, Michel P, Lièvre A, Ducreux M, Gaujoux S, Guiu B, Huguet F, Lecomte T, Lepage C, Louvet C, Maggiori L, Mariani P, Aparicio T, Bouché O
Dig Liver Dis. 2020 Dec 16:S1590-8658(20)31050-1. doi: 10.1016/j.dld.2020.11.029. Epub ahead of print. PMID: 33341421

Abstracts

Impact of antibiotics (ATB) on the recurrence of resected colorectal cancer (CRC): Results of EVADER-1 a nation-wide pharmacoepidemiologic study
Benoit Rousseau, Marc Hilmi, Ines Khati, Anthony Turpin, Antoine Andremont, Charles Burdet, Nathalie Grall, Joana Vidal, Philippe Jean Bousquet, Christine Le Bihan
Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 4106-4106.
Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Dur
Alberto F. Sobrero, Thierry Andre, Jeffrey A Meyerhardt, Axel Grothey, Timothy Iveson, Takayuki Yoshino, Ioannis Sougklakos, Jeffrey P. Meyers, Roberto Labianca, Mark P. Saunders, Dewi Vernerey, Takeharu Yamanaka, Ioannis Boukovinas, Eiji Oki, Vassilis Georgoulias, Valter Torri, Andrea Harkin, Julien Taieb, Anthony Frank Shields, Qian Shi
J Clin Oncol 38: 2020 (suppl; abstr 4004) Abstract 4004
FOLFIRINOX de-escalation in advanced pancreatic cancer : a multicenter real-life study
Dewi Vernerey, Aurelia Meurisse, Pascal Hammel, Cindy Neuzillet, Christophe Borg, Anthony Turpin.
Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 4639-4639
RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II st
Romain Cohen, Jaafar Bennouna, Julie Henriques, Christophe Tournigand, Christelle De La Fouchardiere, David Tougeron, Christophe Borg, Thibault Mazard, Benoist Chibaudel, Marie-Line Garcia-Larnicol, Magali Svrcek, Dewi Vernerey, Yves Menu, Thierry Andre
Journal of Clinical Oncology 38, no. 4_suppl (February 01, 2020) Abst 101.
Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients.
Jerome Galon, Fabienne Hermitte, Bernhard Mlecnik, Alessandro Lugli, Carlo Bruno Bifulco, Iris D. Nagtegaal, Arndt Hartmann, Florence Marliot, Marc Van Den Eynde, Michael H. A. Roehrl, Pamela S Ohashi, Eva Zavadova, Toshihiko Torigoe, Prabhudas S. Patel, Yili Wang, Yutaka Kawakami, Francesco Marincola, Paolo Antonio Ascierto, Bernard A. Fox, Franck Pages
Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 4105-4105.
Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database
Zhaohui Jin, Jesse G. Dixon, Hiral D. Parekh, Steven R Alberts, Greg Yothers, Carmen Joseph Allegra, Rachel Kerr, Daniel G. Haller, Aimery De Gramont, Takayuki Yoshino, Eric Van Cutsem, Chris Twelves, Julien Taieb, Leonard B. Saltz, Jean-François Seitz, Thierry Andre, Amit Mahipal, Richard M. Goldberg, Qian Shi, Thomas J. George
J Clin Oncol 38: 2020

Posters

Impact of antibiotics (ATB) on the recurrence of resected colorectal cancer (CRC): Results of EVADER-1 a nation-wide pharmacoepidemiologic study
Benoit Rousseau, Marc Hilmi, Ines Khati, Anthony Turpin, Antoine Andremont, Charles Burdet, Nathalie Grall, Joana Vidal, Philippe Jean Bousquet, Christine Le Bihan
Poster 98
RECIST and iRECIST criteria for the evaluation of nivolumab + ipilimumab combination in patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI/dMMR) metastatic colorectal cancer (mCRC): Results of the GERCOR NIPICOL phase II st
Romain Cohen, Jaafar Bennouna, Julie Henriques, Christophe Tournigand, Christelle De La Fouchardiere, David Tougeron, Christophe Borg, Thibault Mazard, Benoist Chibaudel, Marie-Line Garcia-Larnicol, Magali Svrcek, Dewi Vernerey, Yves Menu, Thierry Andre
The American Society of Clinical Oncology (ASCO) 2020 meeting
Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients
Jerome Galon, Fabienne Hermitte, Bernhard Mlecnik, Alessandro Lugli, Carlo Bruno Bifulco, Iris D. Nagtegaal, Arndt Hartmann, Florence Marliot, Marc Van Den Eynde, Michael H. A. Roehrl, Pamela S Ohashi, Eva Zavadova, Toshihiko Torigoe, Prabhudas S. Patel, Yili Wang, Yutaka Kawakami, Francesco Marincola, Paolo Antonio Ascierto, Bernard A. Fox, Franck Pages
Poster 97

Liste des publications de l’année2019

Articles

AVANT ACCENT: Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
Taieb J, Shi Q, Pederson L, et al. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies
Ann Oncol. 2019;30(9):1466-1471. doi:10.1093/annonc/mdz208

Liste des publications de l’année2018

Articles

Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).
André Thierry, Vernerey Dewi, Mineur Laurent, Bennouna Jaafar, Desrame Jérôme, Faroux Roger, Fratte Serge, Hug de Larauze Marine, Paget-Bailly Sophie, Chibaudel Benoist, Bez Jeremie, Dauba Jérôme, Louvet Christophe, Lepere Céline, Dupuis Olivier, Becouarn Yves, Mabro May, Egreteau Joëlle, Bouche Olivier, Deplanque Gaël, Ychou Marc, Galais Marie Pierre, Ghiringhelli François, Dourthe Louis Marie, Bachet Jean-Baptiste, Khalil Ahmed, Bonnetain Franck, de Gramont Aimery, Taieb Julien for PRODIGE investigators (GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER)
J Clin Oncol. 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5.
Three versus 6 months of oxaliplatin-based adjuvant chemotherapy for patients with stage III colon cancer: disease-free survival results from a randomized, open-label, International Duration Evaluation of Adjuvant (IDEA) France phase III trial
André Thierry, Vernerey Dewi, Mineur Laurent, Bennouna Jaafar, Desrame Jérôme, Faroux Roger, Fratte Serge, Hug de Larauze Marine, Paget-Bailly Sophie, Chibaudel Benoist, Bez Jeremie, Dauba Jérôme, Louvet Christophe, Lepere Céline, Dupuis Olivier, Becouarn Yves, Mabro May, Egreteau Joëlle, Bouche Olivier, Deplanque Gaël, Ychou Marc, Galais Marie Pierre, Ghiringhelli François, Dourthe Louis Marie, Bachet Jean-Baptiste, Khalil Ahmed, Bonnetain Franck, de Gramont Aimery, Taieb Julien for PRODIGE investigators (GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER)
J Clin Oncol. 2018 May 20
Pancreatic cancer : French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC).
Neuzillet C, Gaujoux S, Williet N, Bachet JB, Bauguion L, Colson Durand L, Conroy T, Dahan L, Gilabert M, Huguet F, Marthey L, Meilleroux J, de Mestier L, Napoléon B, Portales F, Sa Cunha A, Schwarz L, Taieb J, Chibaudel B, Bouché O, Hammel P; Thésaurus National de Cancérologie Digestive (TNCD); Société Nationale Française de Gastroentérologie (SNFGE); Fédération Francophone de Cancérologie Digestive (FFCD); Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Société Française de Chirurgie Digestive (SFCD); Société Française d’Endoscopie Digestive (SFED); Société Française de Radiothérapie Oncologique (SFRO); Association de Chirurgie Hépato-Bilio-Pancréatique et Transplantation (ACHBT); Association Française de Chirurgie (AFC).
Dig Liver Dis. 2018 Aug 18
Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFH).
Matysiak-Budnik T, Fabiani B, Hennequin C, Thieblemont C, Malamut G, Cadiot G, Bouché O, Ruskoné-Fourmestraux A.
Dig Liver Dis. 2018 Feb;50(2):124-131. doi: 10.1016/j.dld.2017.12.006. Epub 2017 Dec 18. Review.
Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).
Zaanan A, Bouché O, Benhaim L, Buecher B, Chapelle N, Dubreuil O, Fares N, Granger V, Lefort C, Gagniere J, Meilleroux J, Baumann AS, Vendrely V, Ducreux M, Michel P; Thésaurus National de Cancérologie Digestive (TNCD). Dig Liver Dis. 2018 Aug;50(8):768-779. doi: 10.1016/j.dld.2018.04.025
Epub 2018 Jun 6. Review.
Impact of primary tumor sidedness on erlotinib efficacy in patients with metastatic colorectal cancer treated with bevacizumab maintenance: Results from the DREAM phase III trial
Benoist Chibaudel, Thierry Andre, Benoit Samson, Marie-Line Garcia-Larnicol, Jérôme Dauba, Gerard Lledo, Olivier Jean Marie Dupuis, Yves Rinaldi, May Mabro, Nathalie Aucoin, Frédéric Viret, Nicole Tubiana-Mathieu, Ahmed Khalil, Ghaouti Nabil Baba Hamed, Werner Scheithauer, Elisabeth Carola, Dewi Vernerey, Christophe Louvet, Aimery De Gramont, Christophe Tournigand,
J Clin Oncol 36, 2018 (suppl 4S; abstr 737)
Oxaliplatin, 5FU and nab-paclitaxel as neoadjuvant regimen in patients with resectable oesogastric adenocarcinoma: A GERCOR phase 2 study (FOXAGAST).
Sarah Sophie Watson, Christelle De La Fouchardiere, Stefano Chong Hun Kim, Romain Cohen, Jean-Baptiste Bachet, Christophe Tournigand, Jean-Marc Ferraz, Marine Lefevre, Delphine Colin, Magali Svrcek, Aurelia Meurisse, Christophe Louvet; Institut Mutualiste Montsouris, Paris, France; Centre Léon-Bérard, Lyon, France; Centre Hospitalier-Universitaire de Besançon, Besançon, France; Saint-Antoine Hospital, Paris, France; Hospital Pitié-Salpêtrière, Paris, FR; Hôpital Mondor, AP-HP, Créteil, France; AP-HP, hôpital Saint-Antoine, Paris, FR; CHU Besancon, Besancon, France
J Clin Oncol 36, 2018 (suppl; abstr 4035)
Association of postoperative carcinoembryonic antigen (CEA) levels with survival in stage III colon cancer (CC): Post hoc analysis of the MOSAIC and PETACC-8 studies
E Auclin, J Taieb, C Lepage, T Aparicio, R Faroux, E Mini, G Folprecht, R Salazar, M Banzi, C Louvet, J-L Van Laethem, J Tabernero, T Hickish, A De Gramont, T Andre, D Vernerey
Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 3568-3568.

Abstracts

Traitement adjuvant des cancers coliques (CC) de stade III: Trois ou six mois de fluoropyrimidines plus oxaliplatine? Résultats de l’étude internationale IDEA
Taieb, A. Grothey, A. Sobrero, T. Iveson, J.A. Meyerhardt, T. Yoshino, I. Souglakos, D. Vernerey, L. Mineur, J. Bennouna, J. Desrame, R. Faroux, S. Fratte, S. Paget-Bailly, J. Dauba, C. Louvet, O. Dupuis, Y. Becouarn, O. Bouché, L.M. Dourthe, F. Bonnetain, A de Gramont, Q. Shi, T. André
Plenary oral session (CO.30) »

Liste des publications de l’année2017

Articles

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).
Kim S, Jary M, André T, Vendrely V, Buecher B, François E, Bidard FC, Dumont S, Samalin E, Peiffert D, Pernot S, Baba-Hamed N, El Hajbi F, Bouché O, Desrame J, Parzy A, Zoubir M, Louvet C, Bachet JB, Nguyen T, Abdelghani MB, Smith D, De La Fouchardière C, Aparicio T, Bennouna J, Gornet JM, Jacquin M, Bonnetain F, Borg C.
BMC Cancer. 2017 Aug 25;17(1):574
Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP).
Moureau-Zabotto L, Vendrely V, Abramowitz L, Borg C, Francois E, Goere D, Huguet F, Peiffert D, Siproudhis L, Ducreux M, Bouché O.
Dig Liver Dis. 2017 Aug;49(8):831-840
Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label,randomised phase 2 trial.
Bachet JB, Hammel P, Desramé J, Meurisse A, Chibaudel B, André T, Debourdeau P, Dauba J, Lecomte T, Seitz JF, Tournigand C, Aparicio T, Meyer VG, Taieb J, Volet J, Monier A, Bonnetain F, Louvet C.
Lancet Gastroenterol Hepatol. 2017 May;2(5):337-346
Rectal cancer: French Intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO).
Gérard JP, André T, Bibeau F, Conroy T, Legoux JL, Portier G, Bosset JF, Cadiot G, Bouché O, Bedenne L; Société Française de Chirurgie Digestive (SFCD), Société Française d’Endoscopie Digestive (SFED0), Société Française de Radiothérapie Oncologique (SFRO).
Dig Liver Dis. 2017 Apr;49(4):359-367

Abstracts

Oxaliplatin-based chemotherapy for patients with stage III colon cancer: Disease Free Survival results of the three versus six months adjuvant IDEA France Trial.
Thierry Andre, Franck Bonnetain, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Roger Faroux, Jérôme Dauba, Dewi Vernerey, Nasredine Aissat, Christophe Louvet, Céline Lepère, Olivier Jean Marie Dupuis, Yves Becouarn, May Mabro, Joëlle Egreteau, Olivier Bouche, Gael Deplanque, Marc Ychou, Aimery De Gramont, Julien Taieb, GERCOR, FFCD, and UNICANCER (PRODIGE)
Oral presentation; Abstract: 3500; Citation: J Clin Oncol 35, 2017 (suppl; abstr 3500)
Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
Qian Shi, Alberto F. Sobrero, Anthony Frank Shields, Takayuki Yoshino, James Paul, Julien Taieb, Ioannis Sougklakos, Rachel Kerr, Roberto Labianca, Jeffrey A. Meyerhardt, Franck Bonnetain, Toshiaki Watanabe, Ioannis Boukovinas, Lindsay A. Renfro, Axel Grothey, Donna Niedzwiecki, Valter Torri, Thierry Andre, Daniel J. Sargent, Timothy Iveson; Mayo Clinic Cancer Center, Rochester, MN; IRCCS San Martino – IST, Genoa, Italy; Wayne State University, Karmanos Cancer Institute, Detroit, MI; Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital, Chiba, Japan; University of Glasgow, Cancer Research UK Clinical Trials Unit, Glasgow, United Kingdom; Hopital Européen Georges Pompidou, Paris, France; University of Heraklion, Athens, Greece; University of Oxford, Oxford, United Kingdom; Ospedale Papa Giovanni XXIII, Bergamo, Italy; Dana-Farber Cancer Institute, Boston, MA; Methodology and Quality of Life Unit, Department of Oncology, INSERM UMR 1098, University Hospital of Besancon; French National Platform Quality of Life and Cancer, Besançon, France; Department of Surgical Oncology and Vascular Surgery, the University of Tokyo, Tokyo, Japan; Bioclinic Thessaloniki Medical Oncology Unit, Thessaloniki, Greece; Mayo Clinic, Rochester, MN; Duke University, Durham, NC; IRCCS – Mario Negri Institute for Pharmacological Research, Milan, Italy; Medical Oncology Department, Saint-Antoine Hospital, Paris, France; University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom)
Plenary Session ; Abstract: LBA1; Citation: J Clin Oncol 35, 2017 (suppl; abstr LBA1)
Three versus six months’ adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: Per-protocol, subgroups and long-lasting neuropathy results
Taieb F. Bonnetain L. Mineur J. Bennouna J. Desrame R. Faroux S. Fratte J. Dauba D. Vernerey C. Louvet
Abstract: A473O; Annals of Oncology, Volume 28, Issue suppl_5, 1 September 2017
Nab-paclitaxel plus gemcitabine or plus simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic adenocarcinoma: A GERCOR randomized phase II study (AFUGEM).
Olivier Dubreuil , Jean Baptiste Bachet , Pascal Hammel , Jerome Desrame , Aurelia Meurisse , Thierry Andre , Philippe Debourdeau , Jérôme Dauba , Thierry Lecomte , Jean Francois Seitz , Christophe Tournigand , Thomas Aparicio , Véronique Guerin Meyer , Julien Taïeb , Sandrine Hiret , Julien Volet , Amandine Monier , Benoist Chibaudel , Franck Bonnetain , Christophe Louvet ;
Abstract:350, Journal of Clinical Oncology 35, no. 4_suppl (February 2017) 350-350.
Neutrophil count and efficacy of chemoradiation in patients with locally advanced unresectable pancreatic carcinoma: An ancillary study of in the LAP 07 trial.
Antoine Schernberg, Dewi Vernerey, David Goldstein, Jean Luc Van Laethem, Bengt Glimelius, Paul Van Houtte, Franck Bonnetain, Christophe Louvet, Pascal Hammel, Florence Huguet
Abstract: 4120; Citation: J Clin Oncol 35, 2017 (suppl; abstr 4120)
Impact of circulating and tissue biomarkers in patients with metastatic colorectal cancer treated with first-line FOLFOX-aflibercept therapy. Results of the GERCOR VELVET Phase II Study
Annemilai Tijeras-Raballand, Armand de Gramont, Marielle Chiron, Jean-Baptiste Bachet, Thierry Andre, Dominique Auby, Jerome Desramé, Baba-Hamed Nabil, Lecaille Cedric, Valérie Lebrun, Christophe Louvet, Annette Larsen, Christophe Tournigand, Sylvie Benner, Malika Attia, Aimery de Gramont, Franck Bonnetain and Benoist Chibaudel
Abstract 2734: July 2017 Volume 77, Issue 13 Supplement

Posters

Docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: A phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study)
Kim (Besançon, France) E. Francois (Nice, France) F. Bidard (Paris, France) E. Samalin (Montpellier, France) F. El Hajbi (Lille, France) N. Baba-Hamed (Paris, France) S. Dumont (Paris, France) S. Pernot (Paris, France) D. Peiffert (Nancy, France) F. Ghiringhelli (Dijon, France) O. Bouche (Reims, France) J. Desrame (Lyon, France) M. Zoubir (Paris, France) A. Parzy (Caen, France) D. Smith (Bordeaux, France) C. De la Fouchardiere (Lyon, France) B. Buecher (Paris, France) V. Vendrely (Bordeaux, France) F. Bonnetain (Besançon, France) C. Borg (Besançon, France)
Poster: 536P